<DOC>
	<DOC>NCT02101177</DOC>
	<brief_summary>The aim of the study is to analyse data coming from two treatment centres of the National Treatment Program Centres of hepatitis C in Egypt</brief_summary>
	<brief_title>Evaluation of the National Treatment Program of Hepatitis C in Egypt</brief_title>
	<detailed_description>Analyse data coming from two centres of the National Treatment Program of hepatitis C in Egypt: - 1500 patients who started treatment between April 1st 2013 and March 31st 2014 and will be seen for their week 60 visit between July 1st 2014 and June 30th 2015 (Cohort A). - 1000 patients recruited between July 1st 2014 and estimated March 31st 2015, of which 200 are expected to be early defaulters and will be contacted by the study team (Cohort B).</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Age &lt; 18 years and &gt; 60 years Positive HCV antibodies using a third generation test Detectable HCV RNA by PCR Liver biopsy showing chronic hepatitis with either a METAVIR score F1 with elevated liver enzymes or scores F2/F3 Naïve to treatment with PEGIFN and RBV HBs antigen negative Prothrombin time ≥60 %, normal bilirubin, alphafoeto protein &lt; 3*normal range of the laboratory, antinuclear antibodies&lt;1/160 Effective contraception during the treatment period; no breastfeeding Signed informed consent and willingness to participate in the study Serious comorbid conditions such as severe hypertension, heart failure, significant coronary heart disease, poorly controlled diabetes (HbA1C&gt;8%) , chronic obstructive pulmonary disease Major uncontrolled depressive illness Solid transplant organ (renal, heart, or lung) Untreated thyroid disease History of previous antiHCV therapy Body mass index (BMI) greater than 30 kg/m² Known human immunodeficiency virus (HIV) coinfection: although HIV testing will not be proposed or done, patients with known HIV coinfection will not be included in the trial hypersensitivity to one of the two drugs (PEGIFN, RBV) pregnancy or unwilling to comply with adequate contraception breastfeeding neutropenia (&lt;1500/mm3) anaemia (&lt;11g/dL for women ; &lt;12g/dL for men) thrombocytopenia (&lt;100.000/mm3) elevated creatinin (&gt;1.5mg/dL) concomitant liver disease other than hepatitis C (immunoactive chronic hepatitis B, autoimmune hepatitis, alcoholic liver disease, hemochromatosis, alpha1 antitrypsin deficiency, Wilson disease) liver biopsy showing severe steatosis (&gt;66%) and steatohepatitis; decompensated cirrhosis (Child Pugh&gt;A); hepatocellular carcinoma, METAVIR score F4. TSH&gt;5 mU/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Viral Hepatitis C</keyword>
	<keyword>Genotype 4</keyword>
	<keyword>SVR</keyword>
	<keyword>Egyptian National Program</keyword>
</DOC>